Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: A new window into personalized medicine

Progress in Pediatric Cardiology

Volumn 37, Issue 1-2, 2014, Pages 23-27

  Bernstein, Daniel ^a   Burridge, Paul ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Cancer; Cardiomyocytes; Doxorubicin cardiotoxicity; ROS; Stem cells

Indexed keywords

EID: 84914705722     PISSN: 10589813     EISSN: 15581519     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2014.10.006     Document Type: Review

References (56)

1. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
2. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
3. Von Hoff D.D., Layard M.W., Basa P., Davis H.L., Von Hoff A.L., Rozencweig M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
4. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
5. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-815.
6. Grenier M., Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25(Suppl. 10):72-85.
7. Kremer L.C., van der Pal H.J., Offringa M., van Dalen E.C., Voute P.A. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002, 13:819-829.
8. van der Pal H.J., van Dalen E.C., Hauptmann M., Kok W.E., Caron H.N., van den Bos C., et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010, 170:1247-1255.
9. Krischer J.P., Epstein S., Cuthbertson D.D., Goorin A.M., Epstein M.L., Lipshultz S.E. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997, 15:1544-1552.
10. Felker G.M., Thompson R.E., Hare J.M., Hruban R.H., Clemetson D.E., Howard D.L., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
11. Piegari E., De Angelis A., Cappetta D., Russo R., Esposito G., Costantino S., et al. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Basic Res Cardiol 2013, 108:334.
12. Huang X., Wu S.M. Isolation and functional characterization of pluripotent stem cell-derived cardiac progenitor cells. Curr Protoc Stem Cell Biol 2010, [Chapter 1:Unit 1 F10.1-1F10.14].
13. Shi Y., Moon M., Dawood S., McManus B., Liu P.P. Mechanisms and management of doxorubicin cardiotoxicity. Herz 2011, 36:296-305.
14. Venditti P., Balestrieri M., De Leo T., Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res 1998, 38:695-702.
15. Xu X., Persson H.L., Richardson D.R. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005, 68:261-271.
16. Holmberg S.R., Williams A.J. Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res 1990, 67:272-283.
17. Fajardo G., Zhao M., Berry G., Wong L.J., Mochly-Rosen D., Bernstein D. Beta2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways. J Mol Cell Cardiol 2011, 51:781-789.
18. Ventura-Clapier R., Garnier A., Veksler V. Energy metabolism in heart failure. J Physiol 2004, 555:1-13.
19. Goormaghtigh E., Brasseur R., Huart P., Ruysschaert J.M. Study of the adriamycin-cardiolipin complex structure using attenuated total reflection infrared spectroscopy. Biochemistry 1987, 26:1789-1794.
20. Suliman H.B., Carraway M.S., Ali A.S., Reynolds C.M., Welty-Wolf K.E., Piantadosi C.A. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 2007, 117:3730-3741.
21. Ueno M., Kakinuma Y., Yuhki K., Murakoshi N., Iemitsu M., Miyauchi T., et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 2006, 101:151-158.
22. Zhang S., Liu X., Bawa-Khalfe T., Lu L.S., Lyu Y.L., Liu L.F., et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012, 18:1639-1642.
23. Granger C.B. Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?. Circulation 2006, 114:2432-2433.
24. Visscher H., Ross C.J., Rassekh S.R., Barhdadi A., Dube M.P., Al-Saloos H., et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012, 30:1422-1428.
25. Visscher H., Ross C.J., Rassekh S.R., Sandor G.S., Caron H.N., van Dalen E.C., et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013, 60:1375-1381.
26. Nagasawa K., Nagai K., Ohnishi N., Yokoyama T., Fujimoto S. Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr Drug Metab 2001, 2:355-366.
27. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 2001, 276:2914-2927.
28. Zeller T., Wild P., Szymczak S., Rotival M., Schillert A., Castagne R., et al. Genetics and beyond-the transcriptome of human monocytes and disease susceptibility. PLoS One 2010, 5:e10693.
29. Cambien F. Personal communication 2013.
30. Okazaki T., Javle M., Tanaka M., Abbruzzese J.L., Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010, 16:320-329.
31. Iulianella A., Lohnes D. Chimeric analysis of retinoic acid receptor function during cardiac looping. Dev Biol 2002, 247:62-75.
32. Kashyap V., Laursen K.B., Brenet F., Viale A.J., Scandura J.M., Gudas L.J. RARgamma is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells. J Cell Sci 2013, 126:999-1008.
33. Delacroix L., Moutier E., Altobelli G., Legras S., Poch O., Choukrallah M.A., et al. Cell-specific interaction of retinoic acid receptors with target genes in mouse embryonic fibroblasts and embryonic stem cells. Mol Cell Biol 2010, 30:231-244.
34. Blanco J.G., Sun C.L., Landier W., Chen L., Esparza-Duran D., Leisenring W., et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol 2012, 30:1415-1421.
35. Blanco J.G., Leisenring W.M., Gonzalez-Covarrubias V.M., Kawashima T.I., Davies S.M., Relling M.V., et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008, 112:2789-2795.
36. Bains O.S., Karkling M.J., Lubieniecka J.M., Grigliatti T.A., Reid R.E., Riggs K.W. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther 2010, 332:755-763.
37. Lakhman S.S., Ghosh D., Blanco J.G. Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 2005, 33:254-257.
38. Wojnowski L., Kulle B., Schirmer M., Schluter G., Schmidt A., Rosenberger A., et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112:3754-3762.
39. Rossi D., Rasi S., Franceschetti S., Capello D., Castelli A., De Paoli L., et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 2009, 23:1118-1126.
40. Lal S., Wong Z.W., Sandanaraj E., Xiang X., Ang P.C., Lee E.J., et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 2008, 99:816-823.
41. Armenian S.H., Ding Y., Mills G., Sun C., Venkataraman K., Wong F.L., et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 2013, 163:205-213.
42. Cascales A., Pastor-Quirante F., Sanchez-Vega B., Luengo-Gil G., Corral J., Ortuno-Pacheco G., et al. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist 2013, 18:446-453.
43. Rajic V., Aplenc R., Debeljak M., Prestor V.V., Karas-Kuzelicki N., Mlinaric-Rascan I., et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009, 50:1693-1698.
44. Lipshultz S.E., Lipsitz S.R., Kutok J.L., Miller T.L., Colan S.D., Neuberg D.S., et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer 2013, 119:3535-3562.
45. Merkle F.T., Eggan K. Modeling human disease with pluripotent stem cells: from genome association to function. Cell Stem Cell 2013, 12:656-668.
46. Gonzalez R., Lee J.W., Schultz P.G. Stepwise chemically induced cardiomyocyte specification of human embryonic stem cells. Angew Chem Int Ed 2011, 50:11181-11185.
47. Lian X., Hsiao C., Wilson G., Zhu K., Hazeltine L.B., Azarin S.M., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 2012, 109:E1848-E1857.
48. Tohyama S., Hattori F., Sano M., Hishiki T., Nagahata Y., Matsuura T., et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013, 12:127-137.
49. Burridge P.W., Keller G., Gold J.D., Wu J.C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012, 10:16-28.
50. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010, 363:1397-1409.
51. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812.
52. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234.
53. Sun N., Yazawa M., Liu J., Han L., Sanchez-Freire V., Abilez O.J., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012, 4:130ra47.
54. Lan F., Lee A.S., Liang P., Sanchez-Freire V., Nguyen P.K., Wang L., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013, 12:101-113.
55. Jung G., Bernstein D. hiPSC modeling of inherited cardiomyopathies. Curr Treat Options Cardiovasc Med 2014, 16:320.
56. Matsa E., Sallam K., Wu J.C. Cardiac stem cell biology: glimpse of the past, present, and future. Circ Res 2014, 114:21-27.